High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.
暂无分享,去创建一个
J. Izopet | L. Meyer | F. Bailly | J. Molina | K. Lacombe | É. Rosenthal | A. Taburet | J. Bronowicki | L. Piroth | D. Zucman | D. Rey | J. Aboulker | E. Billaud | A. Diallo | C. Vincent | Mélanie Simony | Hubert Paniez